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Abstract Heavy alcohol use is commonplace among HIV-
infected individuals; however, the extent that alcohol use
adversely impacts HIV disease progression has not been
fully elucidated. Fairly strong evidence suggests that heavy
alcohol consumption results in behavioral and biological
processes that likely increase HIV disease progression, and
experimental evidence of the biological effect of heavy
alcohol on simian immunodeficiency virus in macaques is
quite suggestive. However, several observational studies of
the effect of heavy alcohol consumption on HIV progres-
sion conducted in the 1990s found no association of heavy
alcohol consumption with time to AIDS diagnosis, while
some more recent studies showed associations of heavy
alcohol consumption with declines of CD4 cell counts and
nonsuppression of HIV viral load. We discuss several
plausible biological and behavioral mechanisms by which
alcohol may cause HIV disease progression, evidence from
prospective observational human studies, and suggest
future research to further illuminate this important issue.
Keywords Alcohol . HIV disease progression . CD4 . HIV
viral load . Adherence . Prospective studies . Nutrition .
Immune activation . Bacterial translocation
Introduction
Heavy alcohol use is commonplace among HIV-infected
individuals and its impact upon behaviors and the course of
disease has been examined over the past two decades [1–3].
However, the extent that alcohol use results in deleterious
effects on the progression of HIV disease has not been fully
elucidated. Although alcohol may directly affect HIV
disease progression in multiple ways, obtaining data to
document its overall impact and contributions associated
with specific mechanisms is difficult. Alcohol consumption
has direct effects on several aspects of the immune system;
yet, experimental studies to assess more directly its impact
on HIV disease have been limited to the related model of
simian immunodeficiency virus (SIV) in primates. In
humans, observational studies may be hampered by
measurement error and confounding. Incomplete assess-
ment of behavioral (eg, other substance use, medication
adherence, nutritional deficiencies) and psychosocial (eg,
depressive symptoms) factors associated with HIV disease
progression impedes rigorous determination of alcohol’s
direct effects. In addition, traditional analytic methods may
fail to account for the potential feedback loop between
alcohol consumption and health status (ie, that alcohol
consumption tends to decrease as health declines). In this
article we review the empirical studies and the major
mechanisms by which alcohol may affect HIV disease
progression (Fig. 1) based on the literature available as of
early 2010.
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HIV Disease Progression: Definitions
Progression of HIV infection in humans or SIV infection in
the HIV primate model has been defined most typically in
terms of viral load, CD4 cell count, AIDS-defining clinical
end points (eg, opportunistic infections), and mortality.
More recent evidence of the association of the level of
immune activation with clinical outcomes is increasingly
recognized; however, few data exist at present to consider
this marker of HIV disease progression. In this literature
review we sought published research that provided mea-
surement of alcohol consumption as well as one of the
following measures of HIV disease progression: HIV viral
load, CD4 cell count, opportunistic infections, or death.
Alcohol Use: Definitions
Alcohol use can be defined by the amount consumed (eg,
at-risk, heavy) or by the consequences of its use (eg, abuse,
dependence). The consumption threshold for at-risk use as
defined by the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) is >4 drinks on an occasion or >14
drinks in a week for men, >3 and >7 respectively, for
women [4]. This level of drinking has been used to define
“heavy” drinking for those with HIV infection [5••],
although its use was chosen based on NIAAA’s use of the
at-risk levels in the general population and was not specific
for HIV-infected individuals. The category of “moderate”
alcohol consumption is used for one whose alcohol use falls
between abstinence (ie, no use of alcohol) and heavy use.
Another dimension to recognize when defining alcohol
use is the variable nature of its use, in that for almost half of
an HIV-infected cohort of persons with a history of alcohol
problems, use was observed to increase or decline over a
median period of 3.4 years [6]. Studies that only measure
drinking at baseline fail to account for the dynamic nature
of alcohol consumption, which may adversely affect study
results and conclusions.
Biological Basis for Alcohol Affecting HIV Disease
Progression
The Effects of Alcohol on the Immune System
Chronic alcohol consumption has been shown to be
associated with increased susceptibility to infectious dis-
eases (eg, tuberculosis and bacterial pneumonia), increased
severity of diseases (eg, viral hepatitis), and increased risk
of cancers (eg, hepatocellular carcinoma) [7]. These ill-
nesses may also be accelerated by vitamin deficiencies,
malnutrition, or other substance use. Chronic alcohol
consumption can lead to liver disease and cirrhosis, which
can impact immunocompetence. Recent animal and human
studies have shown that alcohol consumption has deleteri-
ous effects on both the innate and the acquired immune
responses. Impaired innate immune responses may cause
susceptibility to infection, while impaired acquired immune
responses such as impaired B lymphocyte function, altered
cytokine balance, and chronic T-cell activation may
accelerate disease progression, including that caused by
HIV. In addition, alcohol may play a role in translocation of
bacteria and bacterial products from the gut to cause HIV
immune activation, resulting in increased HIV disease
progression [8].
Alcohol and Nutrition
Micro-nutrient (ie, vitamin and mineral) deficiencies,
including selenium and vitamins D, A, B-12, and E, zinc,
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and iron, have been associated with more rapid HIV disease
progression [9–11]. At the same time, antiretroviral therapy
(ART) is thought to decrease some and restore other
micronutrient levels [12, 13]. Overall nutritional status has
been associated with HIV progression in several prospec-
tive studies [14–16], while there is also an effect of HIV
infection on nutritional status [17]. Alcohol consumption is
associated with nutritional deficiencies, due to a high
percentage of caloric intake from alcohol, decreased
absorption of nutrients, and interference with the metabo-
lism of nutrients [18]. Therefore, it is plausible that
nutritional deficiency is a mechanism by which alcohol
might result in more rapid HIV disease progression. The
link between alcohol use, decreased nutrition, and immune
markers has been demonstrated experimentally in the SIV
model [19]; however, it is not clear for HIV infection in
humans.
Alcohol and ART Effectiveness
Some ART, including non-nucleoside reverse transcriptase
inhibitors and protease inhibitors, is metabolized by the
human cytochrome P450 system. There is evidence that
alcohol may impact the metabolism of these medications by
two different mechanisms, enzymatic induction [20],
associated with chronic alcohol use, and enzymatic inhibi-
tion due to competition of ethanol for various cytochrome
P450 isozymes, associated with acute ethanol use [21].
Because numerous drugs are metabolized by the P450
pathway, chronic alcohol users may be at higher risk for
drug toxicities and ineffective therapy due to inadequate
plasma drug concentration. Chronic alcohol consumption
may also alter drug protein binding. We examine the
evidence as to whether heavy alcohol consumption reduces
the effectiveness of ART as measured by failure to achieve
viral suppression, even with good adherence.
Behavioral/Psychosocial Basis for Alcohol Affecting
HIV Disease Progression
Several behavioral and psychosocial factors that are associ-
ated with heavy alcohol consumption are also associated
with HIV disease progression, and therefore should be
considered when conducting multivariate modeling. We
summarize these associations in the following sections.
Access to and Retention in HIV Care and Receipt of ART
Researchers in the United States and internationally have
found that heavy drinkers are less likely than others to be
receiving ART [22•, 23, 24••]. This may be a consequence
of barriers to consistent medical treatment or due to
physicians’ impressions that heavy drinkers are unable to
competently use ART. Indeed, heavy alcohol use was
independently associated with lower retention in care
among indigent patients [25]. Because early and consistent
HIV care and receipt of opportunistic infection (OI)
prophylaxis and ART are key factors in slowing the
progression of HIV [26], these findings suggest one
mechanism by which heavy alcohol consumption may
accelerate HIV disease progression.
ART Adherence
Alcohol consumption has been consistently associated with
poorer ART adherence. A recent meta-analysis found that
those who used alcohol or drank relatively more were
50%–60% as likely to be classified as adherent compared
with those who abstained or drank relatively less [27•].
Some studies have found a dose-response relationship
between alcohol consumption and ART adherence [24••,
28], in addition to a temporal association between drinking
episodes and missed doses [28]. As ART adherence is a
known predictor of HIV outcome, this strongly suggests
that decreased adherence is one mechanism by which
alcohol may increase HIV disease progression. These
findings elevate the importance of attempting to control
for ART adherence in examining the biological impact of
alcohol on HIV disease progression apart from its impact
on adherence. However, adherence is challenging to
accurately measure and therefore may pose problems even
if included in statistical models. Alternatively and likely
more effectively, studies of persons infected with HIV who
are not yet on ART may reveal key insights about this
important issue.
Alcohol and Comorbidities
Comorbidities may complicate the issue of alcohol’s impact
on HIV disease progression and make it difficult to
determine the association. For example, depression, which
can be exacerbated by the effects of alcohol [29], has been
shown to reduce adherence to ART [30], and depression,
stress, and trauma may have worsening effects on HIV
progression [30, 31].
Illicit substance use is strongly associated with heavy
alcohol consumption, especially in minority and inner-city
populations. Several studies have shown associations
between illicit substance use, especially crack cocaine,
and HIV progression [32•, 33]. Substance use other than
alcohol has also been associated with lower rates of receipt
of ART [24••]. Hence, controlling for other non-alcohol
substance use is important in seeking an understanding of
the impact of alcohol consumption on HIV disease
progression.
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Evidence of a Causal Association between Alcohol Use
and HIV Disease Progression
Experimental Studies
The direct impact of alcohol consumption on HIV disease
progression has been studied using animal models. The
strengths of these studies include the absence of ART
adherence as a possible mediator of disease progression,
and the capacity to control the quantity of alcohol
consumed as well as behavioral factors (eg, nutrition),
which are not easily accounted for in human studies.
Evidence from studies in macaques suggests that heavy
alcohol consumption has consequences for increased SIV
progression. Experimental administration of the equivalent
of heavy doses of alcohol as compared to sucrose to
macaques infected with SIV was associated with early
plasma CD4 cell loss in some studies [34, 35] but not
others [36, 37], while several studies found greater SIV
viral load at various times post-infection [19, 34, 36, 37].
Bagby et al. [36] found a significantly more rapid onset of
end-stage disease in eight alcohol-administered macaques
compared with eight controls. Higher viral load in alcohol-
exposed macaques was associated with a higher percentage
of SIV target cells (CD4) in the gut coupled with lower
percentages of CD8 cells, creating a blunted mucosal
immune response in early infection in one study [37]. The
alcohol-exposed group consumed significantly fewer calo-
ries than the controls in another study [19]. Taken together,
these findings suggest a biologically deleterious effect of
heavy alcohol administration on disease progression in SIV-
infected primates.
Human Observational Studies: Pre-Highly Active
Antiretroviral Therapy (HAART)
A number of clinical studies assessed alcohol use in cross-
sectional and prospective analyses. Associations between
HIV outcomes such as CD4 cell counts and HIV viral load
in cross-sectional studies may reflect differences in the time
of study entry by alcohol consumption category, therefore
we will focus in this review on prospective studies. Several
prospective studies were published using data collected in
the pre-HAART era, as described below.
An analysis conducted in the Multicenter AIDS Cohort
Study (MACS) included 1706 HIV-infected men, and
examined alcohol consumption by average number of
drinks per day, ranging from zero to greater than two, the
latter meeting the threshold for “heavy” drinking in men.
There was no association between drinks per day both at
enrollment and prospectively and the development of AIDS
[38]. A later analysis of the MACS determined that
decreasing alcohol consumption (ie, having a significantly
negative slope in the average number of drinks per week in
the prior 6 months) was associated with developing AIDS-
related conditions, suggesting a decrease in alcohol con-
sumption as HIV progressed [39]. Studies conducted in
men in the Netherlands [40] and Norway [41] found no
association between the number of drinks per day in the
prior 6 months or daily drinking, respectively, with the
development of AIDS. A study of vitamin deficiencies (n=
312) reported that in a multivariate model that included age,
HIV-related symptoms, baseline CD4 cell count, and
several vitamin concentrations, frequent alcohol consump-
tion (>2 times/week) at study baseline was associated with
increased time to CD4 cell count declines to 200 cells/mm3
and time to AIDS [42]. A study of 403 persons serocon-
verting during the Tricontinental Seroconverter Study found
that any alcohol use during the first three quarters of the
follow-up period, limited to avoid the feedback loop
between symptoms and alcohol consumption, was not
associated with time to AIDS or death [43]. The selection
of “any alcohol use” as a main independent variable, as in
the latter study, is a coarse measure to assess alcohol’s
impact on HIV disease progression. All of the preceding
studies were conducted among men who had sex with men.
Two early studies were conducted among injecting drug
users. One study among 496 HIV-infected methadone
maintenance patients found no association between daily
alcohol consumption in the prior month and time to AIDS
or death in a time-dependent multivariate model that
included age, sex, CD4 cell count, zidovudine use, having
two or more symptoms, and crack cocaine use, while crack
cocaine use was independently associated with progression
to AIDS [44]. A study conducted among 188 injection drug
users found that very heavy alcohol consumption (>21
drinks per week) at baseline was associated with increased
%CD8 cells 2–5 years after seroconversion; no impact on
CD4 cell count or %CD4 was found [45].
The only study of the issue from a developing country
was a cohort study of 105 HIV clinic patients who were not
on ART, conducted in Zimbabwe. This study showed no
association between any alcohol consumption at baseline
and successive CD4 cell count and HIV viral loads over a
period of 6 months; however, follow-up was quite limited
and changes in these outcomes were not examined [46].
In summary, in the pre-HAART era, no association of
alcohol use with more rapid HIV disease progression was
identified; however, some studies’ measurement of alcohol
consumption was limited in detail or only measured at
baseline, and the studies largely examined men.
Human Observational Studies: Post-HAART Studies
Studies conducted after the introduction of HAART
differed from the earlier studies in that most used CD4 cell
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count and/or HIV viral load as the study outcomes, an
understandable strategy given the reduction in OI and death
in the HAART era. Notably, these studies either stratified
by or controlled for ART use, and the measurement of
alcohol use was more detailed than in the previous studies.
Chander et al. [24••] reported observations among 1711
persons enrolled in an urban HIV clinic cohort from 1998–
2003. They found that heavy alcohol use in the prior
6 months alone and combined with injection drug use was
associated with decreased viral load suppression after
adjusting for age, race, nadir CD4 cell count, and years
on ART. Controlling for self-reported adherence in these
analyses attenuated the effect of heavy drinking, providing
evidence for the causal chain between alcohol and HIV
outcomes via ART adherence. Because the attenuation of
the effect from a 24% to a 14% reduction in odds of viral
suppression was accompanied by somewhat wider confi-
dence intervals and due to the imprecise nature of ART
adherence measurement, these data are inconclusive as to
whether there is an effect of alcohol on viral suppression
beyond that attributed to poorer adherence.
An analysis of participants in two cohorts of a total of
595 HIV-infected persons with a history of alcohol
problems examined CD4 cell counts and HIV viral loads
at 6-month intervals for up to 7 years [5••]. Upon regression
analysis, among subjects not on ART, heavy alcohol
consumption was associated with a lower CD4 cell count,
on average a difference of 49 cells/mm3. There was no
association between heavy alcohol consumption and CD4
cell count among those on ART, in analyses that adjusted
for baseline CD4, adherence to ART, homelessness,
depressive symptoms, and several other variables. Heavy
alcohol use was not associated with HIV viral load in those
on ART and those not on ART. All analyses among those
on ART adjusted for 3-day self-reported adherence,
suggesting that there is no detectable alcohol effect beyond
the effect on adherence among those on ART. However, the
CD4 cell count difference suggests that there might be an
effect of heavy alcohol consumption on HIV progression
among those not on ART.
A recent publication by Baum et al. [47••] examined the
association between alcohol consumption and HIV out-
comes in a cohort of active alcohol or illicit drug users. In
this study, frequent alcohol consumption (defined as ≥ 2
drinks/day on average) compared to moderate alcohol use
and abstention was associated with a decline of CD4 cell
count to less than 200 cells/mm3, among those who had a
baseline CD4 cell count of greater than 200 cells/mm3. The
model in this study controlled for baseline CD4 cell count,
HIV viral load, ART status, years since tested HIV positive,
age, and gender. A similar model that examined the same
factors but was restricted to those not on ART showed a
stronger association. The effect size was also larger when
the predictor variable was the combination of frequent
alcohol use and crack cocaine use; however, the indepen-
dent effects of alcohol and crack cocaine use were not
shown. In addition, frequent alcohol consumption was
associated with increased HIV viral load in a multivariate
model controlling for the same variables as above except
viral load. However, when stratifying by ART the associ-
ation was significant only among those on ART, and the
authors suggested that the association was mediated by
adherence. These analyses are in contrast to a recent
analysis of the same cohort, which found that crack cocaine
use but not alcohol use, coded only as current yes versus
no, was associated with HIV progression [33]. This
illustrates the importance of using a more detailed alcohol
consumption history to ascertain the relationship of alcohol
use and HIV disease progression.
Two studies in women in the post-HAART era failed to
find an association between alcohol consumption and HIV
outcomes. A recent study of 516 women in the HIV
Epidemiologic Research Study (HERS) cohort examined
the effects of alcohol consumption (ie, none, moderate, and
heavy) on both depressive symptoms and CD4 cell count
[48••]. The analysis showed significant associations be-
tween both moderate and heavy alcohol consumption and
depressive symptoms and between depressive symptoms
and CD4 cell count. The direct association between alcohol
consumption and CD4 cell count was not statistically
significant. The indirect effects of alcohol consumption on
CD4 cell count via depression were not reported; therefore,
we cannot comment on effect of alcohol on CD4 cell count
via the effect on depression. In addition, a large study of
1686 HIV-positive women in the Women’s Interagency
HIV Study (WIHS) found that there was no positive
association between heavy alcohol consumption and time
to newly acquired AIDS-defining illnesses or AIDS-related
death, in repeated measures models that adjusted for crack
use, ART use and adherence, CD4 cell count at baseline,
HIV viral load at baseline, year of HIV diagnosis, and
demographic variables [32•]. This study found a strong
association of persistent crack use and AIDS-related
mortality and both persistent and intermittent crack use
and newly acquired AIDS illnesses. This result is consistent
with other studies that included crack use in multivariate
models [33, 34].
Lastly, a study conducted multivariate modeling of the
effect of drink types on HIV viral load suppression, CD4
cell count, and thymus volume in 165 patients after
24 weeks of ART [49••]. In models that controlled for
demographics, baseline Centers for Disease Control and
Prevention HIV stage, and adherence, heavy alcohol
consumption was not associated with the outcomes while
consuming predominantly liquor compared to beer or wine
was associated with lack of HIV viral suppression,
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decreased thymus size, and change in CD4 cell count. This
study highlights a potential future area of interest, that is,
impact of alcohol beverage type.
In summary, we identified six studies in the post-HAART
era, and three demonstrated an association between heavy
alcohol use and at least one measure of HIV disease
progression [5••, 24••, 47••].
Discussion
Overall, we found that there is strong biological plausibility
that heavy alcohol consumption might hasten HIV disease
progression. We touched on several biological mechanisms
by which this might occur, including direct immunological
effects of alcohol, interactions and competitions with drugs,
nutritional intake, and metabolic deficiencies. In addition,
we reviewed behavioral factors by which alcohol consump-
tion could affect HIV progression, such as reduced/poor
retention in HIV care, adherence, nutrition, and mental
health. Given this strong evidence, one would expect that
simple bivariate analyses would show strong associations
between heavy alcohol consumption and HIV outcomes,
and these associations would be attenuated when causal
pathway variables are included in the model. However, this
is not the case in most of the analyses reviewed above.
Instead, pre-HAART studies showed no associations be-
tween heavy alcohol consumption and HIV outcomes,
while some but not all of the later studies did find such
an association. There are several possible explanations for
these findings.
First, several of the early studies measured alcohol
consumption at baseline, yet alcohol consumption changes
over the course of HIV infection [6]. Such a misclassifica-
tion of the exposure could cause an association to be
obscured. However, for the studies that included time-
dependent measures of heavy alcohol consumption, the
feedback loop between declining health and subsequent
declining alcohol consumption might have counteracted
any deleterious effects of alcohol on disease progression.
While some studies attempted to address that issue, by
measuring changes in alcohol consumption or only mea-
suring alcohol consumption in the first several years after
diagnosis, current statistical methods such as marginal
structural models may be more powerful in detecting
associations [50]. This feedback loop may not have been
an issue in the later studies, because ART is usually started
before patients develop any outward signs of disease
progression. Another issue is that some of the earlier studies
focused on any or current alcohol consumption, rather than
heavy alcohol consumption, which may explain the lack of
associations in these studies if heavy alcohol consumption is
needed to accelerate HIV disease progression.
Another possible issue is that the risk profile of the
populations studied changed over time, with a shift from
predominantly men who had sex with men, to inner-city
clinic patients and poly-substance users. The latter groups
of patients may have engaged in heavier levels of alcohol
consumption or other illicit drug use which was associated
with HIV disease progression.
Another possible explanation for the lack of association
in the early studies is that the outcome measures shifted
over time from AIDS-defining illnesses to biological
markers of immunological decline (CD4) or viral replica-
tion. If alcohol has a direct effect on immune function, then
it is more likely that there will be a significant association
when CD4 cell count is used as the outcome variable.
Lastly, it is important to consider the possibility that
publication bias became a more pervasive issue as the
AIDS epidemic wore on. It seems quite conceivable that
researchers evaluated associations between alcohol con-
sumption and HIV disease outcomes in their cohorts, but
did not pursue these analyses to the stage of publication if
the findings were not statistically significant. Because this
question is still unresolved, we suggest an analysis of
existing cohort study datasets, taking into account the
measurement and analysis issues raised above.
Given the ubiquitous nature of alcohol use among the
people of the world who are infected with HIV, quantifying
the impact of alcohol consumption on HIV disease
progression has major implications on the AIDS epidemic
if even only a modest effect is found. Hence, in addition to
taking optimal advantage of existing data to further
illuminate the relationship of HIV disease and alcohol
use, identifying a cohort in which ART has not been
initiated and in which alcohol is heavily consumed and can
be measured would provide very valuable empirical data.
Such a cohort could provide key insights into this issue,
particularly if the data are collected in a manner that learns
from past studies’ limitations.
Conclusions
The link between alcohol use and HIV disease progression
is clearly complicated to disentangle, and the more recent
empirical evidence is suggestive but not strong. Although
alcohol-related behavior appears to impact HIV disease
progression through ART adherence, biological mecha-
nisms are also likely to be implicated. Future studies should
continue to investigate this important topic in order to
provide clearer evidence, ultimately with the goals of
utilizing the most valid measurement and statistical techni-
ques and furthering our understanding by carefully control-
ling for confounding and meanwhile examining
mechanisms of action. These studies are crucial so that
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the true impact and cost-effectiveness of interventions
designed to slow or prevent alcohol-associated HIV disease
progression can be determined.
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